Maravai LifeSciences (MRVI.US) is one of the best performing Wall Street stocks today. Share price rallies almost 60% after US life science company reported Q4 2023 earnings.
Comparing Q4 2023 results from Maravai LifeSciences with results published by a company a year ago, we can see a big deterioration in business. Revenue dropped by almost two thirds, while adjusted EBITDA plunged over 80% YoY. However, results actually turned out to be a positive surprise, as analysts expected an even bigger deterioration. On an adjusted basis, company managed to avoid reporting a net loss. A provided full-year revenue outlook turned out to be 2-10% better than expected. Analysts noted that Q4 earnings report showed Maravai's buisness may be stabilizing and that full-year outlook looks achievable.
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appQ4 2023 earnings
- Revenue: $74.1 million vs $64.4 million expected (-64% YoY)
- Nucleic Acid Production: $58.8 million vs $50 million expected (-69% YoY)
- Biologics Safety Testing: $15.3 million vs $11.4 million expected (-0.7% YoY)
- Gross profit: $39 million vs $30.9 million expected (-74.2% YoY)
- Gross margin: 52.64% vs 46.54% expected (74% a year ago)
- Adjusted EBITDA: $20.5 million vs $11.4 million expected (-84% YoY)
- Adjusted EBITDA margin: 27.67% vs 17.70% expected (63.4% a year ago)
- Adjusted net income: $2.2 million vs -$2.6 million expected (-97.5% YoY)
- Loss per share: $0.80 vs $1.10 expected ($0.35 profit a year ago)
- Adjusted EPS: +$0.01 vs -$0.01 expected (+$0.35 a year ago)
Full-2024 forecast
- Revenue: $265-285 million vs $259 million expected
Maravai LifeSciences (MRVI.US) is surging almost 60% today. Stock launched today's trading in the $6.80 area, with an around-35% bullish price gap. Gains were extended during the cash session with the stock breaking above a medium-term resistance zone in the $7.00 area. Maravai trades at the highest level since mid-October 2023.
Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
